Chronic myeloid leukaemia (CML) inevitably terminates in blast crisis (BC) which is of myeloid phenotype in approximately two-thirds and B-lymphoid in onethird of patients. T cell BC is rare and associated with poor prognosis. We describe the case of a 48-year-old woman with extramedullary T cell lymphoblastic transformation. After treatment with combination chemotherapy she achieved a second chronic phase and underwent an allogeneic BMT from an HLA-matched unrelated donor. At 30 months follow-up she is still in complete molecular remission and in good clinical condition. We conclude that unrelated donor BMT should be considered as a therapeutic option for patients with extramedullary BC. Bone Marrow Transplantation (2000) 26, 1111-1112.
1996. The patient was started on cytoreductive therapy with hydroxyurea followed by interferon ␣ and achieved a partial haematological but no cytogenetic response. In August 1997 she presented with indolent, generalised lymphadenopathy. A lymph node biopsy revealed a diffuse, almost 100% infiltration with CD3-positive lymphoblasts. Karyotyping of lymph node and bone marrow cells showed the Ph chromosome without further aberrations. The BCR-ABL rearrangement was verified by FISH analysis and Southern blotting on lymph node biopsy. Bone marrow aspiration still showed granulocytic hyperplasia without evidence of blastic transformation. Extramedullary T cell blast crisis was therefore diagnosed and treated with daunorubicine, vincristine, cyclophosphamide, cytosine arabinoside, 6-mercaptopurine, prednisolone and prophylactic CNS irradiation, leading to a second chronic phase. As no sibling donor was available the patient underwent transplantation from an unrelated HLA-A, B, DR genotypically identical donor in February 1998. She received cyclophosphamide 60 mg/kg once daily i.v. on days 1 and 2, vepeside 20 mg/kg once daily i.v. on days 4 and 5 and fractionated TBI 13.5 Gy as conditioning and antithymocyte globulin, cyclosporin A and methotrexate as GVHD prophylaxis. The post-transplant course was complicated by grade III acute GVHD, successfully treated with i.v. methylprednisolone. Haematological reconstitution was delayed with a neutrophil count of 1 × 10 9 /l being achieved by day +56. Thirty months post-BMT she remains clinically well in sustained complete haematologic and molecular remission.
Discussion
Blastic transformation of CML is one of the most aggressive and therapy-resistant human leukaemias. T cell lymphoid blast crisis is exceedingly rare and little data concerning its clinical course as well as prognostic factors and treatment approaches are available to date. Most patients have presented with lymphadenopathy and the median time to transformation was 24 months which is much shorter than in myeloid or B cell lymphoid BC, indicating a more aggressive stem cell disorder. 2 Although a response rate of 68% to conventional chemotherapy was reported in patients with T cell BC 2 which is significantly higher than in patients with B cell transformation (49%) or myeloid BC (19%), 1 the long-term outcome is comparably poor as only 12% of patients were reported to be alive at the time of publication. Extramedullary transformation of CML is observed in 10-16% of all cases and is rapidly followed by bone marrow involvement. Eighty percent of the patients died within 6 months after diagnosis of extramedullary BC. 3 The initial reports of extramedullary BC stressed the difficulty of distinguishing these proliferations from (secondary) malignant lymphomas on histologic grounds alone. 4 In order to precisely differentiate both entities, cytogenetic, FISH and Southern blot analyses of a lymph node biopsy were carried out and demonstrated the presence of the Ph chromosome and the BCR-ABL rearrangement. Because of its high sensitivity and the unavoidable contamination with leukaemic blood cells, polymerase chain reaction -the gold standard for monitoring minimal residual disease in CML patients 5 -could not be used as a reliable technique for this purpose.
Lymphoid blast crisis of CML appears to be at least initially more sensitive to standard chemotherapy than myeloid transformation. 6, 7 Achieving a long-lasting remission, however, seems unlikely with this approach. As the favourable treatment-response associated with lymphoid BC is brief with a median survival of 9 months after diagnosis, plans for definitive strategies such as allogeneic BMT should be implemented rapidly. Patients with lymphoid BC without signs of blastic bone marrow involvement are more likely to achieve a second chronic phase with lower toxicity as compared to patients with significant medullary involvement. This may be beneficial with respect to the outcome of subsequent BMT. Whether patients with T cell BC should be treated with neuroprophylaxis requires further investigation. In B cell transformation meningeal involvement was considered as an important cause of relapse in long-term survivors. 8 Although initial reports have shown that BMT in patients with CML in blast crisis is capable of eradicating leukaemia, the procedure was associated with a high transplant-related mortality. 9 Therefore, allogeneic BMT is not offered routinely to this cohort of patients. However, due to improved supportive care in the allogeneic transplant setting, the prognosis of CML patients with BC may also improve as has been shown previously in patients transplanted in first chronic phase.
Recent reports have shown high remission rates after donor leucocyte infusions in patients with chronic phase CML who relapsed after transplantation indicating a graft-versusleukaemia effect. 10 Whether this effect may also operate in patients with T cell BC remains to be investigated.
In conclusion, the favourable clinical outcome in this case demonstrates that unrelated donor BMT may be an option for patients with extramedullary T cell BC.
